Top Chronic Kidney Disease Drugs Companies Advancing Renal Care Innovation

With Industry 4.0 technologies debuting in the healthcare sector, developers in the chronic kidney disease drugs space are showing an incline toward AI-integration in their processes. An example of the same is Insilico Medicine, who in December 2025, struck a collaboration with TaiGen Biotechnology for the exclusive licensing of its ISM4808 AI-designed PHD inhibitor. The solution has been developed for treating anaemia associated with CKD (chronic kidney disease) in Greater China. With such advancements in line, researchers are also striving to underscore the pivotal role in AI in enhancing disease progression prediction. An instance is a study by Carnegie Mellon University researchers, which depicted how doctors could use deep learning, machine learning, and AI models for predicting CKD progression to end stage renal disease.

Chronic kidney disease affects about 10% of the population, according to the National Kidney Foundation, and millions die every year as they cannot have access to affordable treatment. The occurrence of this disease results in the loss of kidney function at a gradual pace. Such a high prevalence rate has elevated the need for developing effective therapeutic drugs and solutions rendering enhanced care. As per a study by Fortune Business Insights, the global market for chronic kidney disease drugs is set to hit USD 67.81 billion by 2034 from USD 33.62 billion in 2026, depicting a CAGR of 9.17% over 2026 to 2034.

A Look at the Major CKD Drug Players

As new opportunities emerge, eminent companies are putting effort in research and development activities and bringing new products to the market. They are also keen to collaborate with other participants that align with their objectives and seek clearances for their offerings from drug regulators such as the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).

The top 10 chronic kidney disease drugs companies and the pivotal strategies that they are understanding for strong footing have been furnished below:

1. AstraZeneca

AstraZeneca, based in the U.K., develops and commercializes prescription medicines, with biopharmaceuticals, oncology, and rare diseases being the major areas. The total revenue of the company in 2025 hit USD 58.7 billion, say figures available on its website. In April 2021, the company’s Farxiga (dapagliflozin) secured the approval of the U.S. FDA for lowering the risk areas for adults with chronic kidney disease facing progression risk. The areas that would note a declined risk comprise end-stage kidney disease, hospitalization for heart failure, cardiovascular death, and a sustained drop in estimated glomerular filtration rate.

2. Bayer AG

Bayer AG offers an extensive array of solutions in the areas of oncology, kidney disorders, hematology, cardiology, and others. With headquarters located in Germany, the chronic kidney disease drugs company is committed to the development of pharma pipelines and emphasizes sustainability. The company was involved in a phase 2 CONFIDENCE trial in June 2025, which was presented at the European Renal Association (ERA) congress. This trial depicted the efficacy of Jardiance (Boehringer Ingelheim and Eli Lilly's SGLT2 inhibitor) and finerenone (Bayer's mineralocorticoid receptor antagonist (MRA)) in CKD patients associated with type 2 diabetes. It was asserted that, when used together, these drugs give better results compared to when either of them is used alone.

3. Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals is known for the development of chronic kidney disease drugs. The Germany-based player launched the EASi-KIDNEY™ Phase III trial program for offering new solutions for patients with the condition. The company, in December 2025, joined hands with Rectify Pharmaceuticals for advancing the development of CKD treatments and other conditions.

4. Eli Lilly and Company

Eli Lilly and Company, with headquarters in the U.S., develops medications for enhancing the lives of individuals ailing with chronic kidney disease. The drug developer’s Jardiance® (empagliflozin) 10 mg tablets received approval of the U.S. FDA in September 2023. Eli Lilly developed the drug alongside Boehringer Ingelheim for bringing down the risk of end stage kidney disease and hospitalization in CKD patients.

5. Novartis AG

Novartis AG develops drugs and solutions for treating patients with kidney disorders. With its base in Switzerland, the chronic kidney disease drugs player introduces options that are likely to enhance dialysis-free life and slow the progression of kidney disease. An example is its oral Fabhalta® (iptacopan), which received FDA approval in March 2025. This solution has been rolled out for treating adults with C3 glomerulopathy (C3G) for the reduction of proteinuria.

6. Calliditas Therapeutics AB

Calliditas Therapeutics AB, which was founded in 2004, has created its mark as a developer of treatment solutions for solid tumors and primary biliary cholangitis (PBC), among other conditions. The company develops products for addressing CKD contributors, including alport syndrome. In December 2023, the Sweden-headquartered company secured the U.S. FDA approval for TARPEYO (budesonide) delayed release capsules. These solutions have been introduced to decrease the kidney function loss in adults with primary IgAN (immunoglobulin A nephropathy) at progression risk.

7. Otsuka Pharmaceuticals Inc.

Otsuka Pharmaceuticals, one of the top 10 chronic kidney disease drugs companies, conducts research for developing drugs for addressing renal and cardiovascular conditions. The company was established in 1964 and has an extensive portfolio that comprises clinical testing equipment, pharmaceuticals, cosmetics, food products, and others. In November 2025, Japan-based company secured the approval of the U.S. FDA for Voyxact, a new drug for patients with autoimmune and chronic kidney disease.

8. GSK plc

With headquarters in the U.K., GSK is known for its innovative offerings developed for bringing effective solutions for preventive care and disease treatment. The product areas of the company span general medicines, vaccines, and specialty medicines. The chronic kidney disease drugs company entered a five-year partnership with Cambridge in October 2024 for improved outcomes for patients with respiratory and kidney disorders.

9. Amgen Inc.

Amgen offers an array of nephrology products with KYRSTEXXA pegloticase, Aranesp darbepoetin alfa, and EPOGEN (epoetin alfa) recombinant, being some of the offerings. The U.S.-based provider of chronic kidney disease drugs is dedicated to bringing innovative solutions for treating kidney ailments. This is evident from its September 2024 announcement for testing MariTide. This obesity drug candidate would be tested in its late-stage trial in patients with kidney, liver, and heart diseases (which are weight-related conditions).

10. Sanofi

Sanofi is known for developing and rolling out advanced therapeutic solutions for treating various disorders. Some of the major operational areas comprise inflammation and immunology, rare diseases, vaccines, rare blood diseases, oncology, and others. In May 2024, the France-based company’s Sanofi Genzyme announced an awareness campaign alongside the American Kidney Fund for enhancing Fabry disease visibility. The campaign would encourage CKD patients with an unknown cause to undergo testing for Fabry disease.

What are the Coming Years Likely to Unfold?

The year 2025 recorded regulatory approvals of several new medications for kidney disorders. With increasing research endeavors and the constant strife for improving the life of patients, the forthcoming years are likely to witness the approval and rollout of new chronic kidney disease drugs. Research institutes are also directing their efforts toward developing therapeutic solutions that would reverse kidney damage. Such initiatives are being undertaken to shift toward potential treatment options against the existing modalities that focus on slowing disease progression and the management of symptoms. The deployment of advanced technologies for better outcomes are poised to enhance future prospects and open new avenues for drug developers.